Benzinga | Jun 11, 2021 08:49AM EDT

Citigroup Maintains Buy on Vertex Pharmaceuticals, Lowers Price Target to $285

Citigroup analyst Mohit Bansal maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and lowers the price target from $325 to $285.